HARVARD BIOSCIENCE INC — Director's Dealing 2012

Dec 21, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2012-12-19

Reporting Person: GREEN DAVID (Director, President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-12-19	Common Stock	M	48146	$3.16	Acquired	1665079	Direct
2012-12-19	Common Stock	S	48146	$4.0380	Disposed	1616933	Direct
2012-12-20	Common Stock	M	73591	$3.16	Acquired	1690524	Direct
2012-12-20	Common Stock	S	73591	$4.0513	Disposed	1616933	Direct
2012-12-21	Common Stock	M	14409	$3.16	Acquired	1631342	Direct
2012-12-21	Common Stock	S	14409	$4.0590	Disposed	1616933	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-19	Stock Option (right to buy)	$3.16	M	48146	Disposed	2013-04-08	Common Stock, par value $0.01 per share (48146)	Direct
2012-12-20	Stock Option (right to buy)	$3.16	M	73591	Disposed	2013-04-08	Common Stock, par value $0.01 per share (73591)	Direct
2012-12-21	Stock Option (right to buy)	$3.16	M	14409	Disposed	2013-04-08	Common Stock, par value $0.01 per share (14409)	Direct

Footnotes

F1: Reflects the weighted average price of the shares sold in the reported transaction. These shares were sold in multiple transactions at prices ranging from $4.0100 to $4.1400, inclusive. The reporting person undertakes to provide to Harvard Bioscience, Inc., any security holder of Harvard Bioscience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Reflects the weighted average price of the shares sold in the reported transaction. These shares were sold in multiple transactions at prices ranging from $4.0000 to $4.1400, inclusive. The reporting person undertakes to provide to Harvard Bioscience, Inc., any security holder of Harvard Bioscience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: Reflects the weighted average price of the shares sold in the reported transaction. These shares were sold in multiple transactions at prices ranging from $3.9300 to $4.0800, inclusive. The reporting person undertakes to provide to Harvard Bioscience, Inc., any security holder of Harvard Bioscience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: Includes (a) a deferred stock award of 66,800 restricted stock units which vest in equal installments on Jan 1, 2013 and Jan 1, 2014; (b) a deferred stock award of 40,312 restricted stock units which vest in equal installments on Jan 1, 2013, Jan 1, 2014 and Jan 1, 2015; (c) a deferred stock award of 88,737 restricted stock units which vest in equal installments on Jan 1, 2013, Jan 1, 2014, Jan 1, 2015 and Jan 1, 2016; and (d) 1,421,084 shares of common stock held by Mr. Green.

F5: Represents exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan.